DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.
DRG and its group companies would like to inform you that we have updated our website privacy policy.
AcknowledgeIf you didn't find what you were looking for, try again!
Decision Resources Group’s analysts looked back at the key cardiovascular, metabolic, renal, and hematological market events that shaped 2018...
In DRG Blog/ January, 2019Understanding Patient Demographics, Treatment Pathways, and Physician Prescribing Behavior How is Chronic Heart Failure Treated Today? Chronic...
In DRG Blog/ December, 2018Insights on the Gut Microbiome, Obesity, and NAFLD: Part I The human gastrointestinal (GI) tract is home to trillions of microorganisms,...
In DRG Blog/ November, 2018The PROs and CONS of Prescription Weight Loss Medications World Obesity Day is on October 11, and it is a timely reminder of the obesity epidemic...
In DRG Blog, Drug Watch/ October, 2018I must admit it, I am surprised by the scale of the risk reduction that Amarin Corporation’s Vascepa (icosapent ethyl) has delivered in the...
In DRG Blog, Drug Watch/ September, 2018Esperion Therapeutics’ lead candidate, bempedoic acid, a novel cholesterol-lowering agent, has made steady progress and could meet an important...
In DRG Blog, Drug Watch/ May, 2018Currently, only liver biopsy can provide a definitive diagnosis of NASH. As such, it is required for clinical trials evaluating novel therapies and...
In DRG Blog, Drug Watch/ March, 2018Overall, 2017 was not exactly a stellar year for the obesity drug market, with more downs than ups, and although the unmet need for novel drug...
In DRG Blog, Drug Watch/ February, 2018Non-alcoholic steatohepatitis (NASH) is fast becoming a highly competitive drug development race; the high prevalence of the disease, the...
In DRG Blog, Drug Watch/ February, 2018Some substance was added to all the hype around non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) in 2017. New...
In DRG Blog, Drug Watch/ February, 2018Although 2017 was not awash with exciting novel therapies or practice-changing research, the importance of managing lipid levels to reduce the risk...
In DRG Blog, Drug Watch/ February, 2018DRG cardiovascular, metabolic, renal, and hematologic (CMRH) disease experts have compiled their top ten market events in 2017. Events run the...
In DRG Blog, Drug Watch/ January, 2018The statin class provided a major breakthrough for managing high cholesterol, a key modifiable risk factor for cardiovascular (CV) disease, and are...
In DRG Blog, Drug Watch/ November, 2017ACC is done for another year, with a multitude of exciting trials presented, including FOURIER, EBBINGHAUS, SPIRE-1 and -2, ORION-1, and CARAT...
In DRG Blog, Drug Watch/ March, 2017A lot of the hype surrounding ACC.17 is due to the release of cardiovascular (CV) outcomes data for Repatha (evolocumab), Amgen’s PCSK9 inhibitor...
In DRG Blog, Drug Watch/ March, 2017We are potentially on the brink of another massive leap forward in terms of cardiovascular (CV) disease prevention. The first of the late-breaking...
In DRG Blog, Drug Watch/ March, 2017Earlier this month saw President Trump call for an overhaul of the FDA and the way it approves drugs, in particular accelerating the drug approval...
In DRG Blog, Drug Watch/ March, 2017High-fat diets are all the rage these days, and ACC.17 has some serious high-fat content on the menu for dyslipidemia devotees. Some of the fare...
In DRG Blog, Drug Watch/ February, 2017Have you ever had that holiday experience, when you thought you were going to receive an amazing gift, but when the big day arrived you got socks?...
In DRG Blog, Drug Watch/ December, 2016Christmas is a time of giving, and non-alcoholic steatohepatitis (NASH) is one disease that keeps on giving. Not only is it highly prevalent and...
In DRG Blog, Drug Watch/ December, 2016Don’t forget to attend on Jan. 19!